Centene Corporation (CNC) Stock Valuation — DCF Analysis
Medical - Healthcare Plans · NYSE
Current Price
$65.19
Intrinsic Value
Outside reliable range
COMPETITIVE MOAT
↑Government Contracts
Centene's substantial reliance on government contracts for Medicare and Medicaid provides a stable, recurring revenue stream. These contracts are difficult for competitors to replicate due to regulatory hurdles and established relationships.
↑Scale and Network Effects
As a large managed care provider, Centene benefits from economies of scale in negotiating provider rates and administrative efficiencies. Its extensive network of healthcare providers offers a competitive advantage in serving diverse populations.
↑Focus on Underserved Markets
Centene's strategic focus on serving low-income and vulnerable populations, often through government-sponsored programs, creates a niche market with less intense competition from traditional commercial insurers.
INVESTMENT RISKS
↓Regulatory and Policy Changes
Centene's business is heavily dependent on government healthcare policies. Changes in Medicare or Medicaid regulations, reimbursement rates, or eligibility criteria could significantly impact profitability.
↓Competition and Margin Pressure
The healthcare insurance market is highly competitive. Centene faces pressure from both large national insurers and smaller regional players, which can lead to compressed profit margins.
↓Execution and Integration Risks
Centene has grown through acquisitions. Integrating new businesses and managing operational complexities across a large, diverse organization presents ongoing execution risks and potential cost overruns.
Base case
CNC base case valuation
Base case assumptions: 20.0% annual growth, 10.0% discount rate, 5x exit multiple, 5 year projection. Data as of 2026-06-12.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the CNC valuation
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for Centene Corporation respond.
Open DCF Calculator for CNCCompany Overview
Centene Corporation functions as a diverse, multinational healthcare organization, primarily dedicated to delivering a comprehensive range of programs and services to underinsured and uninsured individuals throughout the United States. Its Managed Care division provides extensive health plan coverage for people enrolled in various government-sponsored initiatives. These initiatives include Medicaid, the State Children's Health Insurance Program (SCHIP), long-term services and support, foster care, and specialized Medicare-Medicaid plans that cater to individuals dually eligible for both programs, as well as aged, blind, or disabled populations. The broad spectrum of benefits within these health plans encompasses primary and specialty physician care, inpatient and outpatient hospital services, emergency and urgent care, prenatal support, laboratory and X-ray diagnostics, and home-based primary care. Complementary services feature transportation assistance, vision and dental care, telehealth access, immunizations, specialty pharmacy, therapy, social work, nurse advisory support, and care coordination. Additionally, members are covered for prescriptions, limited over-the-counter medications, medical equipment, and essential behavioral health and substance abuse services. This segment also extends its offerings to commercial healthcare products for individuals and employer groups of various sizes. Centene's Specialty Services segment delivers a distinct set of solutions, including pharmacy benefits management (PBM), 24/7 nurse advice lines and after-hours support, vision and dental services, and staffing provisions for correctional systems and other government agencies. This division also serves beneficiaries eligible for the Military Health System. Its clientele for these specialized services spans state programs, correctional institutions, healthcare organizations, employer groups, and other commercial entities. The company delivers its healthcare services through an expansive network comprising primary and specialty care physicians, hospitals, and various ancillary providers. Established in 1984, Centene Corporation is headquartered in St. Louis, Missouri.
Financial Metrics — CNC Stock Valuation Data
Revenue/Share (TTM)
$402.59
FCF/Share (TTM)
$12.90
ROIC (TTM)
-17.7%
ROE (TTM)
-28.7%
P/FCF
5.1x
EV/EBITDA
-5.8x
FCF Yield
19.71%
Debt/Equity
0.76x
Based on trailing twelve-month data, CNC shows a free cash flow per share of $12.90 and a ROIC of -17.7%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 5.1x and FCF yield of 19.71% are important context metrics when evaluating CNC's stock valuation relative to peers.
Frequently Asked Questions
What is the intrinsic value of CNC?
Centene Corporation currently generates $12.90 in free cash flow per share. At the current price of $65.19, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
Is CNC undervalued?
CNC trades at a P/FCF ratio of 5.1x with a free cash flow yield of 19.71%. This relatively low P/FCF may suggest the stock is attractively priced relative to its cash generation. However, whether CNC is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
How do I value CNC stock using DCF?
To perform a DCF valuation on Centene Corporation: (1) Start with the trailing free cash flow per share ($12.90) as the base, (2) project future FCF growth over 5-10 years based on Medical - Healthcare Plans industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting CNC's risk profile — with a debt-to-equity of 0.76x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
What is DCF valuation and how does it apply to CNC?
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For Centene Corporation, this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Medical - Healthcare Plans trends, then discounting those amounts to today's dollars. CNC's ROIC of -17.7% suggests the company may face challenges generating returns above its cost of capital.
How does WACC affect CNC stock valuation?
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For CNC, with a debt-to-equity ratio of 0.76x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of -5.8x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
Learn More
- See CNC PE Valuation → — Earnings-based stock valuation using PE ratio analysis
- DCF Methodology — Step-by-step guide to discounted cash flow analysis
- PE Methodology — Guide to PE ratio stock valuation
- WACC — Understanding the discount rate used in DCF
- Margin of Safety — How to evaluate downside protection
- Intrinsic Value — How to evaluate stock fair value
- How to Calculate Intrinsic Value — Complete guide for investors
Related Valuations
All Healthcare valuationsDCF and P/E value CNC with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-06-12. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.